Clinically, tumor tissue editing can adequately design tumor tissues, a prerequisite for efficacious use of mTOR inhibitors in refractory metastatic uveal melanoma or refractory Hodgkin’s disease with metronomic low-dose chemotherapy and a PPARα/γ agonist (21, 23). This evidence concerns the gene PPARA and neoplasm.